본문 바로가기
KERD
논문KCI 등재

Correspondence on Editorial regarding “Baveno- VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

참고문헌 (10)

  1. Georg Semmler, "Non-invasive tests-based risk stratification: Baveno VII and beyond", Clinical and Molecular Hepatology, 29(1), pp.105~109 (2023), 대한간학회
  2. Yu Jun Wong, "Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients", Clinical and Molecular Hepatology, 29(1), pp.135~145 (2023), 대한간학회
  3. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance", Clin Liver Dis(Hoboken), 12, pp.33~34 (2018)
  4. Lens S, "Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension", J Hepatol, 73, pp.1415~1424 (2020)
  5. European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C : final update of the series", J Hepatol, 73, pp.1170~1218 (2020)
  6. Tosetti G, "Decompensation in direct-acting antiviral cured hepatitis C virus compensated patients with clinically significant portal hypertension : too rare to warrant universal Β-blocker therapy", Am J Gastroenterol, 116, pp.1342~1344 (2021)
  7. Cosmas Rinaldi Adithya Lesmana, "Managing liver cirrhotic complications: Overview of esophageal and gastric varices", Clinical and Molecular Hepatology, 26(4), pp.444~460 (2020), 대한간학회
  8. Ki Tae Yoon, "β-blockers in advanced cirrhosis: More friend than enemy", Clinical and Molecular Hepatology, 27(3), pp.425~436 (2021), 대한간학회[DOI]
  9. Villanueva C, "β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension(PREDESCI) : a randomised, double-blind, placebo-controlled, multicentre trial", Lancet, 393, pp.1597~1608 (2019)
  10. Semmler G, "Non-invasive tests for clinically significant portal hypertension after HCV cure", J Hepatol, 77, pp.1573~1585 (2022)

관련 논문AI추천

Correspondence to editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”Chuan Liu, Gao-Jun Teng, Hong You, Ling Yang, Xiaolong Qi대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Correspondence to editorial 2 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”Haiyu Wang, Jinjun Chen대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”Haiyu Wang, Jinjun Chen대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Correspondence to editorial 3 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”Haiyu Wang, Jinjun Chen대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호From invasive to intuitive: The emerging role of noninvasive models in hepatic decompensation: Editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”Akhil Deshmukh, Rakhi Maiwall대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”Dong Joon Kim, Do Seon Song대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제4호

이 간행물의 다른 논문 (46건)